Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 02 Oct 2017 Status changed from active, no longer recruiting to completed.
- 14 Aug 2015 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov record.
- 27 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2017 to 1 Dec 2017.